Literature DB >> 16036041

Aldosterone in heart failure: pathophysiology and treatment.

Allan D Struthers1.   

Abstract

Aldosterone produces adverse effects on the vasculature (endothelial dysfunction) and on the myocardium (myocardial fibrosis). These effects have adverse clinical consequences that result in increases in deaths caused by sudden death and by progressive heart failure. The Randomized Aldactone Evaluation Study and the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study show this clearly. Aldosterone blockade should become a regular third neuroendocrine-blocking drug in patients with chronic heart failure.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 16036041     DOI： 10.1007/s11897-004-0005-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  9 in total

1.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.

Authors:  R J MacFadyen; C S Barr; A D Struthers
Journal:  Cardiovasc Res       Date:  1997-07       Impact factor: 10.787

2.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors:  C A Farquharson; A D Struthers
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

3.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

6.  Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

Authors:  Myron H Weinberger; Barbara Roniker; Scott L Krause; Robert J Weiss
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

7.  Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Authors:  Bertram Pitt; Nathaniel Reichek; Roland Willenbrock; Faiez Zannad; Robert A Phillips; Barbara Roniker; Jay Kleiman; Scott Krause; Daniel Burns; Gordon H Williams
Journal:  Circulation       Date:  2003-09-29       Impact factor: 29.690

8.  Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.

Authors:  C S Barr; C C Lang; J Hanson; M Arnott; N Kennedy; A D Struthers
Journal:  Am J Cardiol       Date:  1995-12-15       Impact factor: 2.778

9.  Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.

Authors:  C G Brilla; K T Weber
Journal:  Cardiovasc Res       Date:  1992-07       Impact factor: 10.787
  9 in total
  8 in total

1.  Dihydrotestosterone stimulates aldosterone secretion by H295R human adrenocortical cells.

Authors:  Licy L Yanes; Damian G Romero
Journal:  Mol Cell Endocrinol       Date:  2009-01-21       Impact factor: 4.102

2.  Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension.

Authors:  Zeenat Safdar; Aishwarya Thakur; Supriya Singh; Yingqun Ji; Danielle Guffey; Charles G Minard; Mark L Entman
Journal:  J Pulm Respir Med       Date:  2015-10-31

3.  Current Management of Heart Failure with Preserved Ejection Fraction.

Authors:  Akash H Patel; Balaji Natarajan; Ramdas G Pai
Journal:  Int J Angiol       Date:  2022-09-23

4.  Disordered aldosterone-volume relationship in end-stage kidney disease.

Authors:  Andrew S Bomback; Abhijit V Kshirsagar; Maria E Ferris; Philip J Klemmer
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2009-10-28       Impact factor: 1.636

5.  Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart.

Authors:  Y Shimoni; K Chen; T Emmett; G Kargacin
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

6.  Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor.

Authors:  Jyotsna B Pippal; Yizhou Yao; Fraser M Rogerson; Peter J Fuller
Journal:  Mol Endocrinol       Date:  2009-06-18

7.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 8.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.